Lymphocyte Immunophenotyping in Common Variable Immunodeficiency

Status Completed

Clinical Trial Summary

The purpose of this study is to discover if differences in the surface markers of B-cells (antibody producing cells of the immune system) in Common Variable Immune Deficiency (CVID) are related to CVID or its complications/treatment (e.g. bronchiectasis, granulomatous disease, immunoglobulin treatment). The study hypothesis is that the altered B-cell surface markers are related to CVID, and not to the complications or treatment of CVID.

Clinical Trial Description

Common Variable Immune Deficiency (CVID) is a syndrome containing a spectrum of disorders which results in weakened immunity and recurrent infections. The ESID (European Society for Immunodeficiencies) CVID definition includes patients with marked decrease of IgG (at least 2 standard deviations below the mean for age). Patients must also have disease onset at an age over 2 years, absent isohaemagglutinins and/or response to vaccines and other defined causes of hypogammaglobulinaemia must be excluded. The Euroclass system of classifying CVID is the result of a European multicentre trial attempting to develop a consensus of two existing classification schemes of B-cell immunophenotyping. In this paper it was shown that B-cell immunophenotype correlated with coincidence of clinical sequelae and it suggested implementing this to further classify CVID to give prognostic and therapeutic information. However, it has not yet been shown that these alterations in B-cell immunophenotype are the result of CVID itself and not caused by the treatment or complications of CVID (e.g. immunoglobulin replacement therapy, granulomatous disease, bronchiectasis). The aim of this study is to show that alterations in B-cell immunophenotype are caused by CVID itself and not by its complications or treatment. The study will therefore compare CVID patients to suitable control patients with granulomatous disease, bronchiectasis and on long-term immunoglobulin therapy. A control group of normal people will also be included to ensure the assay can detect normality and to show differences between normal people and patients with CVID. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01196702
Study type	Observational
Source	Barts & The London NHS Trust
Contact
Status	Completed
Phase
Start date	September 1, 2020
Completion date	December 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05034900` - Does Addition of Oscillatory Positive Expiratory Pressure (OPEP) Device to a Chest Physiotherapy Program Provide Further Health Benefits in Children With Bronchiectasis?	N/A
Recruiting	`NCT04101448` - Prevalence of Bronchiectasis in COPD Patients
Withdrawn	`NCT03376204` - Pain Mechanisms in Patients With Bronchiectasis
Completed	`NCT02550821` - Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects
Completed	`NCT02656992` - Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis	N/A
Completed	`NCT02048397` - Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis	N/A
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT02282202` - Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD	N/A
Recruiting	`NCT01761214` - Bacteriology and Inflammation in Bronchiectasis	N/A
Recruiting	`NCT02527486` - Seoul National University Airway Registry	N/A
Completed	`NCT01578681` - ELTGOL and Bronchiectasis. Respiratory Therapy	N/A
Completed	`NCT01854788` - 3 Airway Clearance Techniques in Non Cystic Fibrosis Bronchiectasis	N/A
Completed	`NCT00769119` - A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis	Phase 2
Terminated	`NCT00524095` - Bronchiectasis in Chronic Obstructive Pulmonary Disease (COPD) Patients: Role of Prophylaxis	Phase 2
Completed	`NCT01117493` - Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis	N/A
Recruiting	`NCT00129350` - Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation	Phase 1
Completed	`NCT00656721` - Respiratory Mechanics Effects of Flutter Valve in Bronchiectasis Patients	N/A
Completed	`NCT04081740` - Biological Determinants of Sputum Rheology in Chronic Airway Diseases
Enrolling by invitation	`NCT02546297` - Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis	Phase 4
Completed	`NCT03628456` - Effect of HFCWO Vests on Spirometry Measurements	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.